Classical Hodgkin's lymphoma (HL) is generally considered a highly curable disease, with approximately 80 % of patients cured with standard first-line chemotherapy. The standard treatment approach for relapsed/refractory patients is second-line salvage chemotherapy followed by autologous stem cell transplantation (ASCT). About half of all patients undergoing ASCT are rescued and definitely cured by such an approach, but the outcome in patients relapsing or refractory to second-line chemotherapy and ASCT is dismal, with a median survival of less than three years. Therapeutic options for this subset of patients comprise tandem ASCT, reduced-intensity allogeneic stem cell transplantation (allo-SCT) and novel agents. Median overall and progression-free survival rates following allo-SCT have ranged from 27 to 56 % and from 18 to 39 %, respectively, with a treatment-related mortality ranging from 15 to 25 %. Several new compounds have been identified as promising agents for the treatment of patients with relapsed classical HL. These drugs have shown promising activity in a subset of heavily pre-treated relapsed/refractory patients, with response rates and disease control rates exceeding 40 and 70 %. If approved, these compounds will probably change the standard of care, making it possible to develop combination regimens with chemotherapy or other new agents, thus improving efficacy with a decreased toxicity profile.
with patients responding to second-line chemotherapy having a much better outcome than patients with refractory disease, whose relapse rate approaches 80 % in some published series. [9] [10] [11] [12] The concept of chemosensitivity is strictly related to the imaging techniques and criteria used to assess the response to therapy. The advent of functional imaging techniques such as fluorodeoxyglucose-positron emission tomography (FDG-PET) has further improved the reliability of the response evaluation, allowing the early detection of chemoresistance. In fact, the FDG-PET scan after two cycles of chemotherapy (PET-2) is now considered the most powerful prognostic predictor in the first-line setting. 14 Retrospective studies have suggested that this concept also applies to relapsed or refractory patients undergoing second-line chemotherapy and ASCT, but this finding needs to be confirmed in prospective studies (see Table 2 ).
BCV = carmustine-etoposide-cyclophosphamide; BEAM = carmustine-etoposide-cytosine arabinoside-melphalan; BM = carmustine-melphalan; L-PAM = mitoxantrone-L-phenylalanine mustard; M = melphalan; MBE = melphalan-carmustine-etoposide; NE = not evaluated; OS = overall survival; PFS = progression-free survival; TNI = total nodal irradiation; + = positive; -= negative.
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Allogeneic Stem Cell Transplantation
In clinical practice, allogeneic stem cell transplantation (allo-SCT) has so far been offered to patients relapsing after ASCT. The evidence for a graft-versus-lymphoma (GVL) effect is indirect and comes from:
• retrospective comparisons between relapse rates of allo-SCT recipients and ASCT recipients;
• the fact that several groups reported disease regressions following donor lymphocyte infusions; and
• reports on the protective effect of chronic graft-versus-host disease (GVHD).
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The treatment-related mortality observed with myeloablative conditioning regimens remains high and outweighs any survival advantage compared with ASCT. 24 Reduced-intensity conditioning (RIC) regimens are currently being explored with promising results (see Table 3 ). [24] [25] [26] [27] [28] [29] [30] In a recent paper from the European Group for Blood and Marrow
Transplantation, the outcome in 89 HL patients who received RIC 
Monoclonal Antibodies
XmAb2513 and SGN35 -Targeting CD30
CD30, a member of the tumour necrosis factor (TNF)-receptor superfamily, is an attractive target, because it is expressed nearly universally in Hodgkin's and Reed-Sternberg (HRS) cells, with an extremely limited pattern of expression in normal tissues. 32, 33 Results from two clinical studies using first-generation naked 
Rituximab -Targeting CD20
The anti-CD20 monoclonal antibody rituximab was evaluated in the In a subsequent study, the same investigators combined rituximab with adriamycin-bleomycin-vinblastine-dacarbazine (ABVD) chemotherapy to treat patients with newly diagnosed classical HL. 43 Fifty-two patients with newly diagnosed classical HL were treated in a Phase II study. With a median follow-up of 32 months, the estimated event-free survival (EFS) was 82 % and OS was 100 %. Importantly, the EFS improved for all risk categories: for patients with an internationally prognostic score of 0 to 1, the EFS was 92 %; for scores 0 to 2, 86 %; and for scores 3 to 5, 73 %. These findings are currently being confirmed in a multicentre, randomised study comparing ABVD with rituximab plus ABVD.
Daclizumab -Targeting CD25
CD25 is the interleukin-2 receptor (IL-2R) alpha subunit. IL-2R is a growth factor receptor linked to a variety of signalling pathways -Janus 
Novel Small Molecules
Histone Deacetylase Inhibitors
It is well established that post-transcriptional histone modification plays an important role in regulating gene transcription and that such modification is mediated by several enzymes, including histone acetyltransferases (HATs) and HDACs. 55 The balance between HATs and HDACs is critical for regulating the expression and functional status of a variety of proteins involved in cell proliferation, survival, angiogenesis and immunity. Table 4 ). levels. 66 This study confirms that HDAC inhibitors can also determine changes in the tumour microenvironment. with seven patients experiencing grade 3/4 neutropenia and eight having thrombocytopenia; four patients experienced infections during treatment. 68 Taken together, these data suggest that ITF2357 has encouraging clinical activity in relapsed/refractory HL.
MGCD0103 is a novel oral non
Mammalian Target of Rapamycin Inhibitors
The phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR signalling pathway (see Figure 1) is one of the most aberrantly activated survival pathways in cancer, making it an important target for drug development. The therapeutic value of inhibiting the PI3K/Akt/mTOR axis has recently been studied using the oral mTOR inhibitor everolimus in 17 relapsed-refractory patients (intention to treat analysis) (see Figure 2 ).
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Of 15 evaluable patients with relapsed HL treated daily with 10 mg everolimus, seven (47 %) achieved partial responses (see Figure 2 and Table 5 On the basis of these preclinical experiments, bortezomib-based combinations were evaluated in patients with relapsed classical HL.
In the first study, a Phase I trial evaluated the combination of bortezomib with the ifosfamide-carboplatin-etoposide (ICE) regimen in relapsed/refractory HL. 83 Bortezomib was given at doses of 1, 1.3 or 1.5 mg/m 2 on days one and four of each ICE cycle. Twelve patients were enrolled, of whom six achieved PR and three achieved CR, for an overall response rate of 75 %. On the basis of these encouraging data, a randomised Phase II study comparing ICE with bortezomib plus ICE is currently enrolling patients to determine the contribution of bortezomib to the ICE regimen.
In a second study, 18 patients with relapsed HL were treated with bortezomib in combination with gemcitabine. 84 Because of the relatively low response rate (22 %), coupled with treatment-related liver toxicity, the authors concluded that this regimen should not be further developed for the treatment of HL. In a preclinical experiment, the HSP90 small-molecule inhibitor 
Heat Shock Protein 90 Inhibitor 17-AAG
Conclusion
After more than three decades of quiet on the drug development front, several compounds have been identified as promising agents for the treatment of patients with relapsed classical HL. Future research should focus on identifying biomarkers, selecting patients who are likely to respond to these novel agents, incorporating these new agents with existing effective regimens and identifying predictive markers for treatment response. Ultimately, randomised clinical trials will be required to document the impact of these new agents on patients' survival. n
